This WHO Therapeutics and COVID-19: living guideline now includes two recommendations regarding the combination of neutralizing monoclonal antibodies, Casirivimab and Imdevimab: a conditional recommendation in favour of use in non-severe patients (the condition being patients’ risk of severe disease: patients at highest risk represent good candidat...